In both MOLM-13 and MV4-11 cell lines, ENOblock showedsynergy with quizartinib according to Bliss, HSA, and ZIP scores (Fig. 3; dose-response matrices in Fig. S2), suggesting thatENO1 may play a role in primed resistance against FLT3 inhibitors inFLT3-ITD-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.